ERN1 and type 1 diabetes mellitus: Imatinib has been on such pharamacological agent, which has shown to be effective in blunting the hyperactivity of IRE1α, whereby reducing pancreatic β-cell apoptosis, and reversing type 1 diabetes (T1D) in diabetic patients (68).